Skip to main content

Biodexa Pharmaceticals (BDRX) Stock

Biodexa Pharmaceticals Stock Details, Movements and Public Alerts

Stock Details

Biodexa Pharmaceticals (BDRX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $1.77. Over the past 52 weeks, it has ranged between $2.03 and $53.70. This places the current price at 3.3% of its 52-week high and -12.8% above its 52-week low. Recent trading volume was recorded at 123,302. The 14-day Relative Strength Index (RSI) stands at 39.24, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $3.94 by 55.08%. Similarly, it is below its 200-day moving average of $7.93 by 77.68%. The MACD histogram is 0.08, indicating bullish momentum (MACD Line: -0.57, Signal Line: -0.65).

52-Week Range

$53.70 - $2.03

-96.70% from high · +-12.81% from low

Avg Daily Volume

486,408

20-day average

100-day avg: 750,117

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

0.12

EV/EBITDA

0.03

EPS (TTM)

-$27.00

Price to Sales

0.58

Beta

0.96

Less volatile than market

Q:How is BDRX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is BDRX's risk profile compared to the market?
With a beta of 0.96, Biodexa Pharmaceticals is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 0.12 indicates the stock trades below its accounting value, which could signal value or distress.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-8,872,000

Return on Equity

-61.80%

Return on Assets

-39.00%

Revenue Growth (YoY)

-64.10%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is BDRX's business model?
Profitability metrics are not available for this stock.
Q:What are BDRX's recent growth trends?
Biodexa Pharmaceticals's revenue declined by 64.10% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$1.8M

Revenue (TTM)

$83,000

Revenue/Share (TTM)

$0.44

Shares Outstanding

838.79K

Book Value/Share

$24.92

Asset Type

Common Stock

Q:What is BDRX's market capitalization and position?
Biodexa Pharmaceticals has a market capitalization of $1.8M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 838.79K shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does BDRX's price compare to its book value?
Biodexa Pharmaceticals's book value per share is $24.92, while the current stock price is $1.77, resulting in a price-to-book (P/B) ratio of 0.07. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$178.30

9973.45% upside potential

Analyst Recommendations

No analyst ratings available

Q:How reliable are analyst predictions for BDRX?
0 analysts cover BDRX with 0% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $178.30 implies 9973.4% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on BDRX?
Current analyst recommendations:The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 25, 2026, 02:37 AM

Technical Indicators

RSI (14-day)

39.24

Neutral

50-Day Moving Average

$3.94

-55.08% below MA-50

200-Day Moving Average

$7.93

-77.68% below MA-200

MACD Line

-0.57

MACD Signal

-0.65

MACD Histogram

0.08

Bullish

Q:What does BDRX's RSI value tell investors?
The RSI (Relative Strength Index) for BDRX is currently 39.24, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret BDRX's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.57 above the signal line at -0.65, with histogram at 0.08. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($3.94) is below the 200-day MA ($7.93), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jan 23, 2026, 12:31 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for BDRX and get notified when the price changes.

Stay Ahead of the Market with Biodexa Pharmaceticals Alerts

Set up price alerts for Biodexa Pharmaceticals and get notified instantly when the price hits your target. Never miss an important price movement again.